Inclusion criteria for the review required that studies specify the PD-1/PD-L1 inhibitor utilized, describe the underlying malignancy, and report the patient’s age, sex, time to HLH onset, method of HLH diagnosis, treatment administered, and clinical outcomes. This evidence concerns the gene CD274 and hemophagocytic syndrome.